IL6 and plasma cell myeloma: Upregulation of miR-17 downregulates a gene (SOCS-1) which play a critical role in inhibiting IL-6 growth signalling.42 Epigenetic therapy targeting the distinctive signatures in MGUS, myeloma and BD inflammatory cells could therefore have therapeutic potential.